All Posts

Patient accrual has closed. Now, it’s up to participants to continue to complete COMPPARE’s Quality of Life and Side Effects Follow-up Questionnaires.

After four years and 2,524 enrolled patients, the COMPPARE team officially closed patient accrual to the study on October 31, 2022 at 11:59 p.m. EST. “This is an important milestone and we appreciate the patients who have agreed to participate and all of the hard work on the part of…

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,000th photon prostate cancer patient to reach 67% of its photon cohort goal. COMPPARE Partner Site University of Maryland enrolled the 1,000th patient, followed closely by UNC REX Healthcare, Raleigh, NC, which…

If you are a man between the ages of 55 and 69, September is a good time to schedule a prostate screening, one that includes both a PSA blood test and prostate examination. Consider the numbers: Prostate cancer is the most common genitourinary cancer treated by a urologist and the…

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,500th proton prostate cancer patient and has closed enrollment for the proton cohort. This goal was achieved in advance of the projected completion date of July 31, 2022. The proton cohort is divided into two groups: Pragmatic and…

The COMPPARE Coordinating Center announced today that the study achieved 75% enrollment on May 3, 2022. COMPPARE realized both a remarkable overall accrual rate and a exceptional accrual rate of minorities, despite the ongoing challenges presented by COVID-19. In fact, the study stands to become a model for patient-centric clinical…

On November 17, Dr. Nancy Mendenhall, COMPPARE Principal Investigator, and Charles Griggs, Minority Engagement Group Coordinator, participated in a special panel discussion entitled “From Principles to Practice: Building Partnerships for Trust and Equity in Health Research” during the 7th annual meeting of the Patient-Centered Outcomes Research Institute (PCORI). “This year’s…

COMPPARE Principal Investigator Nancy Price Mendenhall, MD, FACR, FASTRO, was invited to speak at the sixth annual Biennial Science of Global Prostate Cancer Disparities in Black Men Conference, held virtually November 10-13, 2021. The Prostate Cancer Transatlantic Consortium launched the event in Jacksonville, FL in 2010. Funded by the National…

The COMPPARE Coordinating Center announced on September 1, 2021 that the study had reached its Pragmatic Proton enrollment goal of 900 patients, completing and closing that arm of the proton cohort. The 900th patient was enrolled by the Proton Therapy Treatment & Research Center of the Loma Linda University Medical…

The latest edition of the COMPPARE CONNECTION is now online.